ABSTRACT
To evaluate the efficacy and safety of IOP reduction in patients with newly diagnosed early open-angle glaucoma.13
To identify risk factors for glaucoma progression.14
Design One center in Malmö, Sweden, selected from a population-based glaucoma screening 255 patients presenting with newly diagnosed early open-angle glaucoma.The randomization period took place between 1993 and 1997.The median follow-up was 6 years and patients with POAG, PEX and normal-tension glaucoma (NTG) were included, with IOP ranging from 13 to 30 mm Hg. The age of the patients was between 50 and 80 years and the median mean deviation was 4 dB. One group was assigned to a 25% IOP reduction with betaxolol 0.5% twice a day and ALT (n 129) and the other group was left untreated (n 126).
